Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer (STARPAC 2)

Sasieni, Peter (Primary Investigator)

Comprehensive Cancer Centre

Project: Research

Status	Finished
Effective start/end date	1/08/2019 → 1/08/2022

Collaborative partners

King's College London
BARTS HEALTH NHS TRUST
Christie NHS Foundation Trust
Greater Glasgow Health Board
Queen Mary University of London (lead)
University of Manchester
University of Glasgow

Funding

MRC Medical Research Council: £3,365.60